Search company, investor...

Yuyu Pharma

yuyu.co.kr

Founded Year

1941

Stage

IPO | IPO

Date of IPO

11/18/1975

Market Cap

104.10B

About Yuyu Pharma

Yuyu Pharma (KRX: 000220) is a Korean healthcare company that develops medicines in fields such as osteoporosis, stroke, and dementia.

Headquarters Location

197, Dongho-ro, Jung-gu Yuyu Building

Seoul, 04598,

South Korea

02) 2253-6600

Missing: Yuyu Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Yuyu Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Yuyu Pharma Patents

Yuyu Pharma has filed 1 patent.

The 3 most popular patent topics include:

  • Androgens and anabolic steroids
  • Androstanes
  • Diseases of the eye and adnexa
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/29/2016

2/18/2020

Trifluoromethyl compounds, Androgens and anabolic steroids, Androstanes, Dosage forms, Prodrugs

Grant

Application Date

12/29/2016

Grant Date

2/18/2020

Title

Related Topics

Trifluoromethyl compounds, Androgens and anabolic steroids, Androstanes, Dosage forms, Prodrugs

Status

Grant

Latest Yuyu Pharma News

Yuyu Pharma aims to grow bigger with dry eye, hair loss drugs

Nov 7, 2022

Posted : 2022-11-06 11:51 Updated : 2022-11-07 08:52 Robert Yu, president and CEO of Yuyu Pharma, speaks during a press conference held on the sidelines of the CPHI exhibition in Frankfurt, Germany, Wednesday. Joint Press Corps By Baek Byung-yeul FRANKFURT ― Robert Yu, president and CEO of Yuyu Pharma, said Wednesday that his mission is to make the company comparable to prominent biopharmaceutical companies in the world. To that end, he said the Korean company is actively diversifying its portfolio by developing new drugs such as a dry eye treatment as well as hair loss medication. "Yuyu Pharma has two pipelines. One is a dry eye treatment and another one is hair loss medication," Yu said during a press conference held on the sidelines of the CPHI exhibition in Frankfurt. "We are currently conducting the Phase 2 clinical trial for the new dry eye drug in the United States with 240 patients. The test results will come out in the first half of 2023," he said. Based on pre-clinical studies, the company said a dose-dependent decrease in several dry eye-associated inflammatory mediators was observed in the cornea and conjunctiva. These findings indicate that its drug eye treatment candidate YP-P10 may have anti-inflammatory activities on dry-eye-induced ocular surface inflammation. "We are also planning to conduct a clinical trial of our hair loss medication. Dutasteride, familiar to Koreans as Avodart, is actually used to treat an enlarged prostate. But, this medication is widely used as a treatment for hair loss in Korea and Japan. The interesting thing is that clinical trials have not been conducted on whether it can be used as a hair loss medication in Europe and the U.S.," he said. "We will hold a meeting with the U.S. FDA (Food and Drug Administration) in the first half of next year to get approval for launching clinical trials on whether this drug can be used to treat hair loss. If approved, we will start clinical trials in 2024," the CEO added. Yu is the grandson of the company's founder, Yu Teuk-han, and son of current Chairman Yu Seung-pil. As a third-generation owner, he said it is his task to challenge new drug developments for the future of the next 80 years of the company, which celebrated its 80th anniversary last year. The company mainly generates its sales from selling pharmaceuticals and health supplements, but its financial situation has worsened due to too much spending on developing new drugs. In 2021, Yuyu Pharma went into the red with an operating loss of 1.6 billion won ($1.12 million). Nevertheless, Yu said that developing new treatments must go on as that will become a turning point for the company. "If we stop developing new drugs, we will be easily able to see operating profit right away. When asked whether we are on the right track in the long run, I think Yuyu Pharma can make it. It is not just about taking on new business. I am risking my life for this business," he said.

Yuyu Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Yuyu Pharma Rank

Yuyu Pharma Frequently Asked Questions (FAQ)

  • When was Yuyu Pharma founded?

    Yuyu Pharma was founded in 1941.

  • Where is Yuyu Pharma's headquarters?

    Yuyu Pharma's headquarters is located at 197, Dongho-ro, Jung-gu, Seoul.

  • What is Yuyu Pharma's latest funding round?

    Yuyu Pharma's latest funding round is IPO.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.